Loading…

Opposing roles of PGD 2 in GBM

The World Health Organization classifies glioblastoma (GBM) as a grade IV astrocytoma. Despite the advances in chemotherapy, surgery, and radiation treatments that improve a patient's length of survival, the overall trajectory of the disease remains unchanged. GBM cells produce significant leve...

Full description

Saved in:
Bibliographic Details
Published in:Prostaglandins & other lipid mediators 2018-01, Vol.134, p.66
Main Authors: Ferreira, Matthew Thomas, Gomes, Renata Nascimento, Panagopoulos, Alexandros Theodoros, de Almeida, Fernando Gonçalves, Veiga, José Carlos Esteves, Colquhoun, Alison
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The World Health Organization classifies glioblastoma (GBM) as a grade IV astrocytoma. Despite the advances in chemotherapy, surgery, and radiation treatments that improve a patient's length of survival, the overall trajectory of the disease remains unchanged. GBM cells produce significant levels of various types of bioactive lipids. Prostaglandin D (PGD ) influences both pro- and anti-tumorigenic activities in the cell; however, its role in GBM is unclear. Therefore, this study aimed to identify the impact of PGD on GBM cell activities in vitro. First we looked to identify the presence of the PGD synthesis pathway through RT-PCR, immunohistochemistry, and HPLC-MS/MS in three GBM cell lines. Then, to observe PGD 's effects on cell count and apoptosis/mitosis (Hoechst 33342 stain), and migration (Transwell Assay), the cells were treated in vitro with physiological (1μM) concentrations of PGD over 72h. HPLC-MS/MS was used to identify the lipid composition of patients with either Grade II/III gliomas or GBM. We identified the presence of endogenous PGD with its corresponding enzymes and receptors. Exogenous PGD both increased cell count (
ISSN:1098-8823